GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (LTS:0AB6) » Definitions » Gross Loan

Hyloris Pharmaceuticals (LTS:0AB6) Gross Loan


View and export this data going back to 2022. Start your Free Trial

What is Hyloris Pharmaceuticals Gross Loan?

Gross Loan only applies to banks.


Hyloris Pharmaceuticals (LTS:0AB6) Business Description

Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.